Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...
Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn ...
Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
Eli Lilly's Chief Scientific Officer Dan Skovronsky says the company wants to take big swings in Alzheimer's, ALS, chronic ...
The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...
There is only one GLP-1 pill on the market, and it's not as effective as Ozempic for weight loss.Grace Cary/Getty Images Eli Lilly competitor Novo Nordisk kicked off the weight-loss drug craze ...
Eli Lilly makes the popular shots Mounjaro and Zepbound. Next, the company says they have a pill coming that could be as powerful as rival Ozempic. The company's head of obesity said the ultimate ...
The weight-loss drug boom has transformed Eli Lilly (LLY), the maker of Zepbound, into the largest healthcare company in the ...
Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...